aTyr Pharma, Inc. (LIFE) Upgraded to “Buy” by Zacks Investment Research
aTyr Pharma, Inc. (NASDAQ:LIFE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Saturday. The brokerage presently has a $4.25 target price on the biotechnology company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 10.39% from the company’s current price.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
LIFE has been the subject of several other research reports. ValuEngine lowered aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies initiated coverage on aTyr Pharma in a research report on Thursday, September 7th. They issued an “overweight” rating and a $7.00 target price for the company. Finally, BMO Capital Markets set a $4.00 target price on aTyr Pharma and gave the stock a “hold” rating in a research report on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $4.42.
aTyr Pharma (NASDAQ:LIFE) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.07. equities research analysts predict that aTyr Pharma will post -2.09 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/11/18/atyr-pharma-inc-life-upgraded-to-buy-by-zacks-investment-research.html.
In related news, CEO John Mendlein purchased 37,736 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were bought at an average price of $2.65 per share, for a total transaction of $100,000.40. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Paul Schimmel purchased 94,336 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was bought at an average price of $2.65 per share, for a total transaction of $249,990.40. Following the purchase, the director now directly owns 40,440 shares in the company, valued at $107,166. The disclosure for this purchase can be found here. Corporate insiders own 33.30% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its stake in shares of aTyr Pharma by 44.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after buying an additional 25,676 shares during the last quarter. Artal Group S.A. purchased a new stake in shares of aTyr Pharma in the 3rd quarter worth approximately $1,263,000. Victory Capital Management Inc. purchased a new stake in shares of aTyr Pharma in the 3rd quarter worth approximately $455,000. Finally, Renaissance Technologies LLC grew its stake in shares of aTyr Pharma by 1.8% in the 1st quarter. Renaissance Technologies LLC now owns 38,800 shares of the biotechnology company’s stock worth $136,000 after buying an additional 700 shares during the last quarter. Institutional investors own 47.01% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.